Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Show other versions (1)
Bibliographic Details
Main Authors: Mohammed A. Osman, Mohammad S. Elkady, Khalid E. Nasr
Format: Article
Language:English
Published: SAGE Publishing 2016-04-01
Series:Clinical Medicine Insights: Oncology
Online Access:http://www.la-press.com/weekly-paclitaxel-versus-three-weekly-paclitaxel-in-recurrent-platinum-article-a5556
id doaj-41ce6d8a0cc9470c9a3b33e5ea241059
record_format Article
spelling doaj-41ce6d8a0cc9470c9a3b33e5ea2410592020-11-25T03:06:44ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492016-04-0120161035415556Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III StudyMohammed A. OsmanMohammad S. ElkadyKhalid E. Nasrhttp://www.la-press.com/weekly-paclitaxel-versus-three-weekly-paclitaxel-in-recurrent-platinum-article-a5556
collection DOAJ
language English
format Article
sources DOAJ
author Mohammed A. Osman
Mohammad S. Elkady
Khalid E. Nasr
spellingShingle Mohammed A. Osman
Mohammad S. Elkady
Khalid E. Nasr
Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
Clinical Medicine Insights: Oncology
author_facet Mohammed A. Osman
Mohammad S. Elkady
Khalid E. Nasr
author_sort Mohammed A. Osman
title Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
title_short Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
title_full Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
title_fullStr Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
title_full_unstemmed Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
title_sort weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase iii study
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2016-04-01
url http://www.la-press.com/weekly-paclitaxel-versus-three-weekly-paclitaxel-in-recurrent-platinum-article-a5556
work_keys_str_mv AT mohammedaosman weeklypaclitaxelversusthreeweeklypaclitaxelinrecurrentplatinumresistantepithelialovarianandperitonealcancersaphaseiiistudy
AT mohammadselkady weeklypaclitaxelversusthreeweeklypaclitaxelinrecurrentplatinumresistantepithelialovarianandperitonealcancersaphaseiiistudy
AT khalidenasr weeklypaclitaxelversusthreeweeklypaclitaxelinrecurrentplatinumresistantepithelialovarianandperitonealcancersaphaseiiistudy
_version_ 1724672748963233792

Similar Items